St Jude

St. Jude Medical, Inc. has gained CE mark approval for a 25 mm iteration of its Portico™ Transcatheter Aortic Heart Valve Implantation System, extending the applicability of the device to more patients for whom transcatheter aortic valve replacement (TAVR) is indicated.

St. Jude Medical, Inc., has initiated a clinical study of the Prodigy™ neurostimulator, the first spinal cord stimulation (SCS) system able to deliver a proprietary mode of stimulation therapy called burst stimulation. The SUNBURST™ study will evaluate whether burst stimulation can be more effective in managing chronic pain than traditional tonic stimulation.

Data presented at the TCT2013 symposium indicates that patients with drug-resistant hypertension treated with the EnligHTN™ Multi-Electrode Renal Denervation System averaged a 24 mmHg reduction in systolic blood pressure as measured in an office setting.

TCT2013 will see St. Jude Medical, Inc. showcasing its newly FDA approved ILUMIEN™ OPTIS™ PCI Optimization™ System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease.

The FDA has issued an alert to health care providers and patients concerning its Amplatzer Atrial Septal Occluder (ASO). It seems that in very rare instances, tissue surrounding the device can erode, resulting in life-threatening emergencies that require immediate surgery.

This time last year the news was filled with externalising ICD lead discussions, focusing to a large degree on St.Jude Medical. It seems a raft of clinical data has helped minimise the negative impact, while a healthy sales line and two exciting new acquisitions mean the company’s financial report is a positive sounding affair.

St.Jude Medical says newly acquired Nanostim’s leadless pacemaker represents one of the most important advances in the history of pacing technology. The deal could cost it $188m

St. Jude Medical, Inc., has gained CE Mark approval of its next-generation EnligHTN™ Renal Denervation System for treating patients with drug-resistant, uncontrolled hypertension. The company promises a time reduction from 24 minutes using its first device, to just 4 minutes.

St. Jude Medical adds ablation catheter with contact-force measurement to its industry-leading atrial fibrillation portfolio and accelerates U.S. timeline for AF ablation indication.

St. Jude Medical, Inc., has seen its MediGuide Enabled™ Ablation Catheters gain U.S. FDA approval. The company is touting reduction in radiation exposure for patients, MediGuide using a previously recorded fluoroscopic map of the target tissue.

St. Jude Medical, Inc. has reported sales and net earnings for the second quarter ended June 29, 2013. Background We … continue reading “Mixed Bag for St.Jude Medical Sees Cardiac Rhythm Business Propped Up by The Rest”

St. Jude Medical, Inc. has gained regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) and launch of the Accent MRI™ Pacemaker and the Tendril MRI™ lead.

St.Jude Medical, Inc. has received CE Mark approval of its next-generation quadripolar device, the Quadra Assura MP™ cardiac resynchronization therapy defibrillator.

Last month St. Jude Medical, Inc. told us it had gained CE mark approval for its next-generation Ellipse™ and SJM … continue reading “FDA Approval For St. Jude’s Ellipse™ and Assura™ ICD/CRT-Ds”

St. Jude Medical, Inc. has made a $40 million equity investment in Spinal Modulation, Inc., a company that has developed … continue reading “St. Jude’s “Try Before You Buy” Deal With Spinal Modulation, Inc.”

St. Jude Medical, Inc. has gained U.S. FDA approval to begin the EnligHTN IV Renal Denervation Study, the first U.S. trial using the EnligHTN™ Multi-Electrode Renal Denervation System to treat patients with drug-resistant high blood pressure.